Rakow John 4
4 · Adverum Biotechnologies, Inc. · Filed Sep 16, 2022
Insider Transaction Report
Form 4
Rakow John
SVP, Genl Counsel, Acting CFO
Transactions
- Award
Stock Option (Right to Buy)
2022-09-14+42,813→ 42,813 totalExercise: $1.09Exp: 2032-09-13→ Common Stock (42,813 underlying) - Award
Performance Based Stock Option (Right to Buy)
2022-09-14+75,257→ 75,257 totalExercise: $1.09Exp: 2032-09-13→ Common Stock (75,257 underlying)
Footnotes (2)
- [F1]The options will vest in equal monthly installments over three years, such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of September 14, 2022, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
- [F2]All of the shares subject to the Performance Based Stock Option shall vest and become exercisable upon certification by the Compensation Committee of the Board of Directors of the Issuer that one full Nasdaq trading session has elapsed since the Issuer's public disclosure of final topline results from the LUNA Phase 2 clinical trial of ADVM-022 in wet age-related macular degeneration (the "Performance Based Stock Option Vesting Date"), provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) from September 14, 2022 through the Performance Based Stock Option Vesting Date.